Nasser Ahmadiasl1, Shokofeh Banaei2, Alireza Alihemmati3, Behzad Baradaran4, Ehsan Azimian5. 1. Drug Applied Research Center, Tabriz University of Medical Sciences, Tabriz, Iran. 2. Department of Physiology, Tabriz University of Medical Sciences, Tabriz, Iran. 3. Department of Histology & Embryology, Tabriz University of Medical Sciences, Tabriz, Iran. 4. Immunology Research Center, Tabriz University of Medical Sciences, Tabriz, Iran. 5. Department of Linguistics and Foreign Languages, Payame Noor University, Tehran, Iran.
Abstract
PURPOSE: Renal ischemia reperfusion (IR) is an important cause of renal dysfunction. It contributes to the development of acute renal failure (ARF). The purpose of this study was to investigate the anti-inflammatory effect of erythropoietin (EPO) and melatonin (MEL), which are known anti-inflammatory and antioxidant agents, in IR-induced renal injury in rats. METHODS: Male Wistar Albino rats were unilaterally nephrectomized and subjected to 45 min of renal pedicle occlusion followed by 24 h reperfusion. MEL (10mg/kg, i.p) and EPO (5000U/kg, i.p) were administered prior to ischemia. After 24 h reperfusion, blood samples were collected for the determination of total antioxidant capacity (TAC), malondialdehyde (MDA) and serum creatinine levels. Also, renal samples were taken for Immunohistochemical evaluation of Bcl2 and TNF-α (tumor necrosis factor-α) expression. RESULTS: Ischemia reperfusion increased creatinine, TAC, MDA levels and TNF-α expression, also, IR decreased Bcl2 expression. Treatment with EPO or MEL decreased creatinine, MDA levels, and increased TAC level. Also, MEL up-regulated Bcl2 expression and down-regulated TNF-α expression compared with EPO. CONCLUSION: Treatment with EPO and MEL had a curative effect on renal IR injury. These results may indicate that MEL protects against inflammation and apoptosis better than EPO in renal IR injury.
PURPOSE:Renal ischemia reperfusion (IR) is an important cause of renal dysfunction. It contributes to the development of acute renal failure (ARF). The purpose of this study was to investigate the anti-inflammatory effect of erythropoietin (EPO) and melatonin (MEL), which are known anti-inflammatory and antioxidant agents, in IR-induced renal injury in rats. METHODS: Male Wistar Albino rats were unilaterally nephrectomized and subjected to 45 min of renal pedicle occlusion followed by 24 h reperfusion. MEL (10mg/kg, i.p) and EPO (5000U/kg, i.p) were administered prior to ischemia. After 24 h reperfusion, blood samples were collected for the determination of total antioxidant capacity (TAC), malondialdehyde (MDA) and serum creatinine levels. Also, renal samples were taken for Immunohistochemical evaluation of Bcl2 and TNF-α (tumor necrosis factor-α) expression. RESULTS:Ischemia reperfusion increased creatinine, TAC, MDA levels and TNF-α expression, also, IR decreased Bcl2 expression. Treatment with EPO or MEL decreased creatinine, MDA levels, and increased TAC level. Also, MEL up-regulated Bcl2 expression and down-regulated TNF-α expression compared with EPO. CONCLUSION: Treatment with EPO and MEL had a curative effect on renal IR injury. These results may indicate that MEL protects against inflammation and apoptosis better than EPO in renal IR injury.
Authors: Glenda Gobé; Xiao-Ju Zhang; Desley A Willgoss; Estelle Schoch; Nicole A Hogg; Zoltán H Endre Journal: J Am Soc Nephrol Date: 2000-03 Impact factor: 10.121
Authors: Juan C Mayo; Rosa M Sainz; Dun-Xian Tan; Rüdiger Hardeland; Josefa Leon; Carmen Rodriguez; Russel J Reiter Journal: J Neuroimmunol Date: 2005-08 Impact factor: 3.478
Authors: María J Tuñón; Beatriz San Miguel; Irene Crespo; Francisco Jorquera; Eva Santamaría; Marcelino Alvarez; Jesús Prieto; Javier González-Gallego Journal: J Pineal Res Date: 2010-10-22 Impact factor: 13.007
Authors: R J Ploeg; J H van Bockel; P T Langendijk; M Groenewegen; F J van der Woude; G G Persijn; J Thorogood; J Hermans Journal: Lancet Date: 1992-07-18 Impact factor: 79.321
Authors: Zorica M Dimitrijevic; Tatjana P Cvetkovic; Vidojko M Djordjevic; Dusica D Pavlovic; Nikola Z Stefanovic; Ivana R Stojanovic; Goran J Paunovic; Radmila M Velickovic-Radovanovic Journal: Int J Med Sci Date: 2012-10-26 Impact factor: 3.738